Table 1.
Sample | Sex | Age (years) | DIF (BMZ) | SSS dermal binding | IB Ln‐332 | IP Ln‐332 | ELISA | IIF (KO skin) | Cancer | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Ln‐332 | Col7 | Col7 | Ln‐332 | ||||||||
1 | M | 54 | IgG 4+, C3c 3+, IgA 2+, IgM 2+ | IgG 3+, IgA+ | Neg | np | np | − | + | − | Yes |
2 | F | 59 | Neg | IgG 2+ | α3, β3 | np | np | − | + | − | No |
3 | M | 65 | IgG 3+, C3c 2+, IgA 1+ | IgG 1+ | α3 | np | np | np | np | np | No |
4 | F | 86 | IgG 3+, C3c 3+, IgA 2+, IgM ± | IgG 1+ | γ2 | np | np | − | + | − | No |
5a | M | 27 | IgG 2+, C3c 3+ | IgG 2+ | α3 | np | + | − | np | np | No |
6a | M | 25 | IgG 3+,C3c 3+ | IgG 2+ | α3 | np | + | − | np | np | No |
7a | F | 65 | IgG 3+, C3c +/2+ | IgG 2+ | α3 | np | + | np | np | np | No |
8a | F | 42 | IgG 3+, C3c 2+ | IgG 2+ | α3 | np | + | − | np | np | No |
9a | M | 70 | IgG 2+ | IgG 1+ | α3 | + | np | np | np | np | Yes |
10 | M | 82 | IgG 3+, C3c 3+ | IgG 3+ | α3, β3, γ2 | np | np | − | np | np | No |
11 | M | 77 | np | IgG 2+ | α3, β3 | np | np | − | + | − | na |
12b | F | 52 | IgG 3+, C3c 3+, IgA 1+ | IgG 2+ | Neg | np | np | − | + | − | No |
13 | M | 81 | np | IgG 3+ | α3 | np | np | np | np | np | na |
14a | M | 56 | IgG 2+, IgA 2+ | IgG dubious | α3 | np | + | np | np | np | Yes |
15 | M | 63 | IgG 3+, C3c 2+ | IgG 1+ | α3 | np | np | np | np | np | na |
16a , c | F | 64 | IgG 3+/4+, C3c +/2+ | IgG 3+ | α3 | − | + | np | np | np | No |
BMZ, basement membrane zone; Col7, type VII collagen; DIF, direct immunofluorescence; ELISA, enzyme‐linked immunosorbent assay; F, female; IB, immunoblot; IIF, indirect immunofluorescence; IP, immunoprecipitation; KFA, keratinocyte footprint assay; Ln‐332, laminin‐332; M, male; na, not available; Neg, negative; np, not performed; SSS, salt‐split skin. IP was performed with radiolabelled human keratinocyte extract.34 IB was performed for all sera on extract of cultured keratinocytes, and for sera of patients 7, 9 and 16 also on human keratinocyte matrix proteins. ELISA for anti‐Col7 was performed with a kit from MBL (Nagoya, Japan) and ELISA for anti‐Ln‐332 was performed on affinity‐purified Ln‐332 as described previously.34 a–cDescribed previously by aTerra et al.;34 bvan den Bos et al.38 and cJonkman et al.37